A carregar...
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. BRCA1/2 mutations occur at 1–7% across biliary tract cancers (BTCs), but a broader spectrum of...
Na minha lista:
| Publicado no: | Medicines (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7555445/ https://ncbi.nlm.nih.gov/pubmed/32878011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicines7090054 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|